Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Xiongjie Jia, Tao Zhang, Junjie Sun, Hengxue Lin, Tianliang Bai, Yating Qiao, Yaxin Li, Gang Li, Guicun Li, Xinyu Peng & Aimin Zhang. (2023) Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy. Pharmacogenomics and Personalized Medicine 16, pages 277-289.
Read now
Read now
Yuguo Liu, Lijuan Luan & Xingli Wang. (2015) A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation. OncoTargets and Therapy 8, pages 1061-1068.
Read now
Read now
Articles from other publishers (3)
Ankush Paladhi, Samrat Daripa, Indrani Mondal & Sumit Kumar Hira. (2022) Targeting thymidine phosphorylase alleviates resistance to dendritic cell immunotherapy in colorectal cancer and promotes antitumor immunity. Frontiers in Immunology 13.
Crossref
Crossref
Giorgia Marisi, Emanuela Scarpi, Alessandro Passardi, Oriana Nanni, Angela Ragazzini, Martina Valgiusti, Andrea Casadei Gardini, Luca Maria Neri, Giovanni Luca Frassineti, Dino Amadori & Paola Ulivi. (2017) Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab. Scientific Reports 7:1.
Crossref
Crossref
Gaetano Romano. (2015) Tumor markers currently utilized in cancer care. Materials and Methods 5.
Crossref
Crossref